Health & Medicine | Jan 17, 2026 | 10 min read | By Bryan White

Evidence Shows Prenatal Paracetamol Does Not Cause Neurodevelopmental Issues (Lancet)

Biology * Public Health * Epidemiology

Introduction: The Clinical Dilemma of Gestational Analgesia and Antipyresis

(Note: This report is for informational purposes only and does not constitute medical advice.) Paracetamol (acetaminophen) is the most widely utilized analgesic and antipyretic agent during pregnancy, taken by 46% to 56% of expectant mothers across developed nations.[1][2] Because alternative analgesics carry substantial gestational contraindications, paracetamol has long served as the first-line pharmacotherapy recommended by obstetricians. Over the past decade, however, unadjusted observational epidemiology studies reported modest statistical correlations (20%-30% elevated hazard or odds ratios) between maternal paracetamol intake and subsequent childhood diagnoses of Autism Spectrum Disorder (ASD), Attention-Deficit/Hyperactivity Disorder (ADHD), and intellectual disability.[1][2][3][4]

Although major teratology bodies such as the European Network of Teratology Information Services (ENTIS), the FDA, and the EMA emphasized that these observational signals suffered from unmeasured confounding,[5][6][7] a controversial 2021 "Consensus Statement" in Nature Reviews Endocrinology[8] and high-profile U.S. product-liability litigation sparked widespread clinical anxiety.[9][10] On January 16, 2026, a landmark systematic review and meta-analysis published in The Lancet Obstetrics, Gynaecology, & Women's Health by Dr. Francesco D'Antonio and colleagues at City St George's, University of London, resolved this controversy.[11] By stratifying 43 studies encompassing millions of pregnancies according to methodological rigor and sibling-comparison controls for shared genetics and familial environment, the review confirms that prenatal paracetamol exposure does not cause ASD, ADHD, or intellectual disability.[11][12]

The 2026 Lancet Meta-Analysis: Sibling-Comparison Stratification

Standard cohort studies that compare unrelated mothers who took paracetamol during embryogenesis or fetal gestation against mothers who abstained cannot fully isolate pharmacological exposure from familial baseline risk.[13][14] To separate causal teratogenicity from familial and clinical noise, D'Antonio et al. (2026) evaluated 43 cohort studies across a strict hierarchy of evidence, prioritizing sibling-comparison designs (discordant exposure between siblings born to the same mother) and low risk-of-bias studies that rigorously controlled for maternal indication and psychiatric history.[11][12]

| Neurodevelopmental Outcome | | Methodological Filter | | Pooled Effect Estimate (95% CI) | | P-Value | | Epidemiological Interpretation |

| Autism Spectrum Disorder (ASD) | | Sibling Comparison (D'Antonio et al., 2026) | |

OR 0.98 (0.93 - 1.03) | | 0.45 | | Null association (no causal risk) |

| Autism Spectrum Disorder (ASD) | | Low Risk of Bias (D'Antonio et al., 2026) | | OR 1.03 (0.86 - 1.23) | | 0.78 | | Null association (no causal risk) |

| ADHD | | Sibling Comparison (D'Antonio et al., 2026) | | OR 0.95 (0.86 - 1.05) | | 0.31 | | Null association (no causal risk) |

| ADHD | | Low Risk of Bias (D'Antonio et al., 2026) | | OR 0.97 (0.89 - 1.05) | | 0.49 | | Null association (no causal risk) |

| ADHD | | Registry Sibling Control (Ahlqvist et al., 2024) | | HR 0.98 (0.94 - 1.02) | | >0.40 | | Null association (complete attenuation) |

| Intellectual Disability | | Sibling Comparison (D'Antonio et al., 2026) | | OR 0.93 (0.69 - 1.24) | | 0.63 | | Null association (no causal risk) |

| Intellectual Disability | | Low Risk of Bias (D'Antonio et al., 2026) | | OR 1.11 (0.92 - 1.34) | | 0.28 | | Null association (no causal risk) |

As the analytical filter moved from unadjusted population cohorts to sibling-controlled and low-bias designs, the apparent 20% excess risk vanished entirely across all three neurodevelopmental outcomes, including cohorts with over five years of longitudinal follow-up,[11][12][15] a conclusion independently reinforced in September 2026 by an umbrella review in Developmental Medicine & Child Neurology.[16]

Deconstructing the Observational Mirage: Confounding and Toxicology

The complete attenuation of risk within discordant sibling pairs demonstrates that earlier observational correlations were artifacts of two classic epidemiological biases -- confounding by indication and shared genetic confounding -- rather than direct fetal neurotoxicity:[11][17]

* Confounding by Indication (Maternal Immune Activation): Expectant mothers take paracetamol specifically to treat pyrexia (fever), infection, or inflammatory pain.[18] Untreated maternal fever and systemic infection trigger Maternal Immune Activation (MIA), releasing pro-inflammatory cytokines such as Interleukin-6 (IL-6) that cross the placenta and perturb fetal microglial pruning and neuron migration.[19][20][21] In crude observational cohorts, paracetamol acts merely as a proxy marker for the underlying inflammatory insult it was taken to mitigate.

* Shared Polygenic Heritability (The ADHD-Pain Overlap): ASD and ADHD exhibit heritability estimates of 70% to 80%. Psychiatric genomics has established a strong polygenic correlation between ADHD risk alleles and heightened chronic pain sensitivity (migraine, musculoskeletal pain).[22] Mothers carrying ADHD risk variants experience higher gestational pain burdens, consume paracetamol more frequently, and transmit those shared risk alleles to their offspring. Comparing exposed and unexposed full siblings holds maternal genotype and household environment constant, neutralizing this genetic confounder.[13]

* Why Proposed Toxicological Mechanisms Fail at Therapeutic Doses: Speculative biological hypotheses had suggested that fetal cytochrome P450 enzymes might convert paracetamol into the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI),

depleting glutathione, inducing oxidative stress, or perturbing epigenetics and endocannabinoid (AM404/TRPV1) signaling.[23][24] In human physiology, however, fetal hepatic CYP2E1 activity is minimal, maternal conjugation (glucuronidation and sulfation) clears therapeutic doses efficiently, and rodent studies reporting neurobehavioral changes relied on supratherapeutic dosing regimes.[9][24]

Regulatory Validation and Comparative Clinical Safety in Pregnancy

The 2026 Lancet meta-analysis provides peer-reviewed validation of U.S. District Judge Denise Cote's December 2023 federal Daubert ruling, which dismissed the multidistrict Tylenol autism litigation after finding that plaintiff experts had cherry-picked confounded observational studies while ignoring sibling-control evidence.[10] (On July 13, 2026, a U.S. Court of Appeals for the Second Circuit panel in Rutledge v. Walgreen Co. vacated that dismissal on procedural Federal Rule of Evidence 702 admissibility grounds -- and denied rehearing on October 16, 2026 before remanding ~550 MDL claims to Judge Cote -- while explicitly stressing it was not deciding scientific causation.[25]) More importantly for public health, restoring clinical confidence in paracetamol prevents expectant mothers from turning to dangerous alternatives -- including untreated high fever (a proven neural-tube and neurodevelopmental teratogen)[21] or contraindicated drug classes:[7][26]

| Analgesic Class | | Representative Agents | | Gestational Window | | Established Fetal & Neonatal Risks | | Clinical Guideline Status |

| Anilide Analgesics | | Paracetamol (Acetaminophen) | | All Trimesters | | None proven at therapeutic doses (ASD/ADHD links refuted by sibling controls). | | First-Line Choice (lowest effective dose for shortest duration). |

| NSAIDs | | Ibuprofen, Naproxen | | 1st & 2nd Trimesters | | Associated with spontaneous abortion and oligohydramnios after 20 weeks. | | Avoid unless specifically indicated under supervision. |

| NSAIDs | | Ibuprofen, Naproxen | | 3rd Trimester (>28 wks) | | Premature closure of fetal ductus arteriosus, pulmonary hypertension, renal failure.[7][27] | | Strictly Contraindicated. |

| Opioids | | Codeine, Oxycodone | | All Trimesters | | Neonatal Abstinence Syndrome (NAS), maternal dependence, respiratory depression. | | Restricted to severe acute pain refractory to paracetamol. |

| Salicylates | | High-Dose Aspirin | | 3rd Trimester | | Fetal hemorrhage, premature ductus arteriosus closure. | | Contraindicated (except 81 mg low-dose preeclampsia prophylaxis). |

Conclusion: The Triumph of Methodological Rigor

The resolution of the prenatal paracetamol controversy illustrates the indispensable role of causal inference design in the evolution of perinatal pharmacoepidemiology.[11][28] By isolating maternal polygenic architecture and febrile indication bias through multi-million-pregnancy sibling comparisons, D'Antonio and colleagues have confirmed that paracetamol remains the safest, most essential first-line analgesic and antipyretic available to protect maternal and fetal health during pregnancy.[11][28]

Updates... (Nov 22, 2026): Added the September 2026 Developmental Medicine & Child Neurology umbrella review (doi:10.1111/dmcn.70512) confirming the null sibling-controlled findings and updated the federal litigation status through October 2026 (the Second Circuit's July 13, 2026 Rule 702 remand in Rutledge v. Walgreen Co. and October 16, 2026 denial of rehearing); completed Lancet (Vol. 2, Issue 3, e190-e198) and Epidemiology (doi:10.1097/EDE.0b013e31825fa230) metadata; corrected Zerbo et al. (Dec 2015) and Frisell (May 4, 2021) publication dates while preserving original print years; replaced unreachable third-party and blog links with JAMA Pediatrics, International Journal of Epidemiology, Nature Reviews Endocrinology, and BMJ sources; and added verified publication dates across all 28 Works Cited entries (including FDA, UK MHRA, AMWA, and Drugwatch).

Works Cited

* [1] Liew, Z., Ritz, B., Rebordosa, C., Lee, P.-C., & Olsen, J. (Apr 1, 2014). Acetaminophen Use During Pregnancy, Behavioral Problems, and Hyperkinetic Disorders. JAMA Pediatrics, 168(4), 313-320. https://doi.org/10.1001/jamapediatrics.2013.4914

* [2] Brandlistuen, R. E., Ystrom, E., Nulman, I., Koren, G., & Nordeng, H. (Oct 24, 2013). Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyt183

* [3] Masarwa, R., Levine, H., Gorelik, E., Reif, S., Perlman, A., & Matok, I. (Aug 1, 2018). Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwy086

* [4] Alemany, S., Avella-Garc a, C., et al. (Oct 2021). Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts. European Journal of Epidemiology. https://doi.org/10.1007/s10654-021-00754-4

* [5] Alwan, S., Conover, E. A., Harris-Sagaribay, L., Lamm, S. H., Lavigne, S. V., et al. (Mar 2022). Paracetamol use in pregnancy -- caution over causal inference from available data. Nature Reviews Endocrinology, 18, 190. https://doi.org/10.1038/s41574-021-00606-x

* [6] U.S. Food and Drug Administration (FDA) (Sep 22, 2025). FDA Responds to Evidence of Possible Association Between Autism and Acetaminophen Use During Pregnancy. https://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminop

* [7] UK Medicines and Healthcare products Regulatory Agency (MHRA) (Jun 27, 2023). Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy. https://www.gov.uk/drug-safety-update/non-steroidal-anti-inflammatory-drugs-nsaids-potential-risks-following-prolonged-use-after-

* [8] Bauer, A. Z., Swan, S. H., Kriebel, D., et al. (Dec 2021). Paracetamol use during pregnancy -- a call for precautionary action. Nature Reviews Endocrinology. https://doi.org/10.1038/s41574-021-00553-7

* [9] Damkier, P., & Hodson, K. (Jun 2022). Shelter from the storm: Acetaminophen (paracetamol) in pregnancy, urogenital malformations, and childhood neurodevelopment. Obstetric Medicine. https://doi.org/10.1177/1753495X221080883

* [10] Drugwatch (updated Nov 17, 2026). Tylenol Autism Lawsuit: November 2026 Updates. https://www.drugwatch.com/drugs/tylenol/lawsuit/

* [11] D'Antonio, F., Flacco, M. E., Valle, L. D., Prasad, S., Manzoli, L., Samara, A., et al. (Mar 2026 [online Jan 16, 2026]). Prenatal paracetamol exposure and child neurodevelopment: a systematic review and meta-analysis. The Lancet Obstetrics, Gynaecology, & Women's Health, 2(3), e190-e198. https://doi.org/10.1016/S3050-5038(25)00211-0

* [12] Mahase, E. (Jan 19, 2026). Paracetamol (Tylenol) in pregnancy: fresh study dispels autism risk. BMJ. https://doi.org/10.1136/bmj.s113

* [13] Frisell, T., berg, S., Kuja-Halkola, R., & Sj lander, A. (Sep 2012). Sibling Comparison Designs: Bias From Non-Shared Confounders and Measurement Error. Epidemiology, 23(5), 713-720. https://doi.org/10.1097/EDE.0b013e31825fa230

* [14] Frisell, T. (May 4, 2021 [online Aug 24, 2020]). Invited Commentary: Sibling-Comparison Designs, Are They Worth the Effort? American Journal of Epidemiology, 190(5), 738-741. https://doi.org/10.1093/aje/kwaa183

* [15] Sheikh, J., Allotey, J., Sobhy, S., et al. (Nov 9, 2025). Maternal paracetamol (acetaminophen) use during pregnancy and risk of autism spectrum disorder and attention deficit/hyperactivity disorder in offspring: umbrella review of systematic reviews. BMJ. https://doi.org/10.1136/bmj-2025-088141

* [16] Tayebi-Hillali, H., Blanco-Su rez, M., Rivas-Mundi a, B., & Limeres-Posse, J. (Sep 23, 2026). Prenatal exposure to paracetamol and the risk of autism and attention-deficit/hyperactivity disorder: An umbrella review and meta-meta-analysis. Developmental Medicine & Child Neurology. https://doi.org/10.1111/dmcn.70512

* [17] Ahlqvist, V. H., Sj qvist, H., Karlsson, H., et al. (Apr 9, 2024). Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability. JAMA. https://doi.org/10.1001/jama.2024.3172

* [18] American Medical Women's Association (AMWA) (Dec 3, 2025). Acetaminophen, Pregnancy, and the Public Health Risk of Misleading Warnings. https://www.amwa-doc.org/acetaminophen-pregnancy-and-the-public-health-risk-of-misleading-warnings/

* [19] Zawadzka, A., et al. (Oct 26, 2021). The Role of Maternal Immune Activation in the Pathogenesis of Autism: A Review of the Evidence, Proposed Mechanisms and Implications for Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222111516

* [20] Zerbo, O., Qian, Y., Yoshida, C., Grether, J. K., Van de Water, J., & Croen, L. A. (Dec 2015 [online Dec 24, 2013]). Maternal Infection During Pregnancy and Autism Spectrum Disorders. Journal of Autism and Developmental Disorders, 45(12), 4015-4025. https://doi.org/10.1007/s10803-013-2016-3

* [21] Antoun, S., Ellul, P., Peyre, H., et al. (Dec 2021). Fever during pregnancy as a risk factor for neurodevelopmental disorders: results from a systematic review and meta-analysis. Molecular Autism. https://doi.org/10.1186/s13229-021-00464-4

* [22] Ciochetti, N. P., de Oliveira, V. F., et al. (Jul 2025). Genetic Interplay Between Attention-Deficit/Hyperactivity Disorder and Pain Suggests Neurodevelopmental Pathways and Comorbidity Risk. Biological Psychiatry Global Open Science. https://doi.org/10.1016/j.bpsgos.2025.100517

* [23] Chu, S., et al. (Sep 3, 2025). Acetaminophen's Role in Autism and ADHD: A Mitochondrial Perspective. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178585

* [24] B hrer, C., Endesfelder, S., Scheuer, T., & Schmitz, T. (Oct 15, 2021). Paracetamol (Acetaminophen) and the Developing Brain. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms222011156

* [25] United States Court of Appeals for the Second Circuit (Jul 13, 2026). Rutledge v. Walgreen Co., Nos. 24-916(L), 24-1121(Con), 24-2360(Con), 24-2594 (Opinion vacating MDL summary judgment under Rule 702). https://ww3.ca2.uscourts.gov/decisions/OPN/24-916_24-2594_redacted_opn.pdf

* [26] U.S. Food and Drug Administration (FDA) (Oct 15, 2020; updated Aug 9, 2024). Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Drug Safety Communication -- Avoid Use of NSAIDs in Pregnancy at 20 Weeks or Later. https://www.fda.gov/safety/medical-product-safety-information/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communic

* [27] Koren, G., Florescu, A., Costei, A. M., Boskovic, R., & Moretti, M. E. (May 1, 2006). Nonsteroidal Antiinflammatory Drugs During Third Trimester and the Risk of Premature Closure of the Ductus Arteriosus: A Meta-Analysis. Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1G428

* [28] Science Media Centre (Jan 16, 2026). Expert reaction to review showing that taking paracetamol during pregnancy does not increase risk of autism, ADHD or intellectual disabilities. https://www.sciencemediacentre.org/expert-reaction-to-review-showing-that-taking-paracetamol-during-pregnancy-does-not-increas